Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2012, Vol. 08 ›› Issue (06): 787 -791. doi: 10.3877/cma.j.issn.1673-5250.2012.06.032

Special Issue:

Review

Updated Progress of Gynecologic Complications in Breast Cancer With Adjuvant Therapy

Li-qin ZENG1(), Qi WANG2, Xiao-li SUN1, Xi-ping LUO1   

  1. 1. Department of Gynecology and Breast Surgery, Guangdong Women and Children Hospital, Guangzhou 510010, Guangdong Province, China
  • Received:2012-09-01 Revised:2011-11-01 Published:2012-12-01
  • Corresponding author: Li-qin ZENG
  • About author:
    (Corresponding author: ZENG Li-qin, Email: )

Adjuvant therapy including endocrine therapy, chemotherapy, prophylactic castration, hormone replacement therapy(HRT) of breast cancer in women frequently causes episodes of reproductive organs, which could be associated with proliferative changes of the endometrium, or even endometrial cancer. Chemotherapy for breast cancer is likely to negatively impact on ovarian function. A number of surveillances and interventions should be done. And we reviewed updated progress of gynecologic complications in breast cancer with adjuvant therapy, including contraception, preservation of infertility, breastfeeding following breast cancer.

[1]
Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008[J]. 2007-11-01].

URL    
[2]
Pagani O, Goldhirsch A. Breast cancer in young women: Climbing for progress in care and knowledge[J]. J Clin Oncol, 2006, 2(5):717-732.
[3]
Lhomme C, Pautier P, Zagame L, et al. Surveillance de l'endomètredes femmessous tamoxifène endometrial surveillance of women on tamoxifen[J]. Gynécol Obstét Fertil, 2003, 31(7-8):647-656.
[4]
Group EBCTC. Tamoxifen for early breast cancer: An overview of the randomised trials[J]. Lancet, 1998, 351:1451-1467.
[5]
Luo YF, Liu YH. Effect on endometrial by tamoxifen[J]. J Reprod Med, 2004, 13(6):338-341.
[6]
Wang C, Wang C, Huang H, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. CA A Cancer J Clin, 2002, 94(8):2192-2198.
[7]
Wen ZQ, Wang QX, Leng QG, et al. Clinical and pathological observations of oral norethisterone treatment of endometrial hyperplasia with menorrhagia[J].Progr Obstet Gynecol, 1999, 8(1):44-46.
[8]
Rose P, Brandewie E, Abdul-Karim F. Failure of megestrol acetate to reverse tamoxifen induced endometrial neoplasia: Two case reports[J]. Int J Gynecol Cancer, 1999, 9(5):362-364.
[9]
Montz F, Bristow R, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer[J]. Am J Obstet Gynecol, 2002, 186(4):651-657.
[10]
Gardner F, Konje J, Abrams K, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial[J]. Lancet, 2000, 356(9243):1711-1717.
[11]
Chan S, Tam W, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG[J].Int J Obstet Gynaecol, 2007, 114(12):1510-1515.
[12]
Gardner F, Konje J, Bell S, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial[J]. Gynecol Oncol, 2009, 114(3):452-456.
[13]
Chin J, Konje J, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen[J]. Cochrane Datab Syst Rev (Online), 2009, 4:20-23.
[14]
Wang S, Zha XM. Effect of tamoxifen on uterus and ovaries of postmenopausal breast cancer patients[J].Acta Univ Med Nanjing, 2001, 21(4):320-321.
[15]
Ji XQ, Sun GZ.Clinical analysis of ovarian cysts cause by tamoxifen treatment for breast cancer[J]. Clin Med China, 2003, 19(7):660-661.
[16]
Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: Reproductive and late health effects of treatment[J]. J Clin Oncol, 2003, 21(22):4184-4193.
[17]
Sun ZY, Shen K, Lang JH, et al. Effect on ovarian function in ovarian cancer patients after chemotherapy of preserve fertility function surgery[J]. Acta Acad Med Sin, 2003, 25(4):431-433.
[18]
Kil WJ, Ahn SD, Shin SS, et al. Treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients. Breast cancer research and treatment[J].Breast Cancer Res Treat, 2006, 96(3):245-250.
[19]
Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer[J]. Cancer Control, 2002, 9(6):466-472.
[20]
Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy[J]. Cur Opin Obstet Gynecol, 2005, 17(1):21-26.
[21]
Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a[J]. JNCI Monographs, 2005, 2005(34):40-43.
[22]
Gwyn K. Children exposed to chemotherapy in utero[J]. JNCI Monographs, 2005, 2005(34):69-71.
[23]
Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer[J]. Breast Cancer Res, 2007, 9(6):115.
[24]
Pritchard KI. Endocrine therapy of advanced disease[J]. Clin Cancer Res, 2003, 9(1):460-467.
[25]
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: Trial stopped[J]. Lancet, 2004, 363(9407):453-455.
[26]
von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial[J]. J Nation Cancer Instit, 2005, 97(7):533-535.
[27]
Sestak I, Kealy R, Edwards R, et al. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms[J]. J Clin Oncol, 2006, 24(24):3991-3996.
[28]
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial[J]. JAMA: J Am Med Assoc, 2002, 288(3):321-333.
[29]
Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors[J]. J Nation Cancer Instit, 2008, 100(7):475-482.
[30]
Madalinska JB, van Beurden M, Bleiker E, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy[J]. J Clin Oncol, 2006, 24(22):3576-3582.
[31]
Chiarelli AM, Kirsh VA, Klar NS, et al. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection[J]. Cancer Epidemiol Biomark Prevent, 2006, 15(10):1856-1862.
[32]
Bordeleau L, Pritchard K, Goodwin P, et al. Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review[J]. Clin Therapeut, 2007, 29(2):230-241.
[33]
Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001[J]. Eur J Cancer, 2005, 41(10):1446-1452.
[34]
El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer[J]. BMC cancer, 2006, 6(1):194.
[35]
Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer[J]. J Clin Oncol, 2004, 22(20):4174-4183.
[36]
Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women[J]. J Am College Surgeons, 2008, 206(6):1193-1203.
[37]
Ives A, Saunders C, Bulsara M, et al. Pregnancy after breast cancer: Population based study[J]. BMJ, 2007, 334(7586):194.
[38]
Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence[J]. Cancer, 2004, 100(3):465-469.
[39]
Avilés A, Neri N. Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero[J]. Clin Lymphom, Myelom Leukem, 2001, 2(3):173-177.
[40]
Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy[J]. Lancet Oncol, 2004, 5(5):283-291.
[41]
Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma[J]. Cancer, 1999, 85(11):2424-2432.
[42]
Trinh XB, Tjalma WAA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients[J]. Fertil Steril, 2008, 90(1):17-22.
[43]
Helewa MLP, Provencher D, Lea R, et al. Breast cancer, pregnancy, and breastfeeding[J]. J Obstet Gynaecol Canada, 2002, 24(2):164-180.
[44]
Sacchini V, Pinotti JA, Barros ACSD, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: Oncologic or technical problem[J]? J Am College Surgeons, 2006, 203(5):704-714.
[1] Wei Hong, Xirong Ye, Zhihong Liu, Yinfeng Yang, Zhihong Lyu. Value of ultrasound radiomics combined with clinicopathological features in predicting complete pathological response to neoadjuvant chemotherapy for breast cancer[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(06): 571-579.
[2] Wei Liu, Yunfeng Niu, Jie An. LINC01232 promotes malignant progression of triple negative breast cancer through miR-516a-5p/BCL9 axis[J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 330-338.
[3] Xiaoyu Zhang, Yulai Yin, Yinxu Zhang. Efficacy and prognostic analysis of apatinib combined with neoadjuvant chemotherapy in triple negative breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 346-352.
[4] Junying Gao, Haizhou Zhang, Hongle Qu, Qiang Sun. Progress in the application of FOLFOX-HAIC-based adjuvant translational therapy for hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 457-463.
[5] Jie Xu, Yajun Li, Yiwen Feng. Comparison of recent follow-up between laparoscopic D2 radical surgery and conventional radical surgery for advanced gastric cancer after SOX neoadjuvant chemotherapy[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 647-650.
[6] Qing Xue, Saiye Shi, Yawen Xu, Xia Sheng, Qinqin Zhang. Application of tracking methodology combined with failure mode and effect analysis in patients with bladder perfusion chemotherapy[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 553-559.
[7] Lei Zhao, Wenzhi Liu, Feng Lin, Jian Yu, Mingjun Sun, Yougang Cui, Xu Zhang, Yupeng Yi, Baosheng Yu, Ning Feng. The study on the effects of deep hyperthermia in improving side effects of adjuvant chemotherapy and quality of life in the patients after colorectal cancer surgery[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 488-493.
[8] Jiagang Han, Zhenjun Wang. The treatment strategies for obstructive left-sided colon cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 450-458.
[9] Yang Shi, Jianfeng Yu, Ke Cao, Zhiwei Zhai, Chunxiang Ye, Zhenjun Wang, Jiagang Han. Perioperative complication analysis of self-expanding metallic stents (sems) combined with neoadjuvant chemotherapy in the treatment of complete obstructive left-sided colon cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 464-471.
[10] Xuanhao Liang, Xiaorong Li, Liang Li, Changwei Lin. Efficacy and prognosis of colonic stenting combined with neoadjuvant chemotherapy for acute obstructive colorectal cancer: a Meta-analysis[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 472-482.
[11] Ying Zhang, Xin Zhao, Jiamei Chen, Yan Li. Impact of preoperative chemotherapy on prognosis of pseudomyxoma peritonei treated by cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy:a meta-analysis[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 826-835.
[12] Qi Liu, Shoukai Wang, Shuai Wang, Yuqing Su, Zhuang Ma, Haijun Chen, Pilei Si. Advances in research of intratumoral microbiome in breast cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 841-845.
[13] Junwei Cui, Huali Cai, Yibin Hu, Hui Hu. Clinical value of methylene blue combined with marker clip and hook-wire localization in evaluation of axillary lymph node metastasis after neoadjuvant chemotherapy for breast cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 625-632.
[14] Yuying Wang, Shiwei Liu, Rui Wang, Yaling Zng, Xihui Tu, Purong Zhang. Predictive factors for pathological complete response to neoadjuvant therapy for breast cancer in elderly patients[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 641-646.
[15] Shuai Wang, Zhiyuan Zhang, Yuqing Su, Wenwen Li, Shoukai Wang, Qi Liu, Wentao Li. Mendelian randomization and its application in breast cancer research[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 671-676.
Viewed
Full text


Abstract